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July 5, 2011:196–201Asians. It may suggest that PPR would be 1 of numerous risk
factors of atherothrombosis and that the role of it may not explain
the whole clinical events after percutaneous coronary intervention.
Previous studies reported that high PPR is associated with poor
clinical outcomes in patients with coronary artery disease (3,4).
owever, it is not clear that tailored dosing or choice of antiplate-
et agents based on platelet function test can improve the prognosis
f patients with high PPR. The GRAVITAS (Gauging Respon-
iveness With A VerifyNow Assay–Impact on Thrombosis and
afety) trial could not show the benefit of high-dose clopidogrel
herapy in patients with high PPR (5). The TRIGGER-PCI
Testing Platelet Reactivity in Patients Undergoing Elective Stent
lacement on Clopidogrel to Guide Alternative Therapy With
rasugrel) study was stopped early after an interim analysis
evealed a primary event rate too low to allow for any meaningful
omparison between clopidogrel and prasugrel (6). The results of
major trials make us question whether PPR would be a
odifiable factor of thrombosis or simply an intrinsic property
eflecting one’s thrombotic status. Further studies are warranted to
nvestigate these unsolved problems, especially regarding the eth-
ic difference of response to antiplatelet regimen and the necessi-
ies of personalized antiplatelet therapies.
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2011.Vasovagal Syncope as a Cause of
Syncope in Long-QT Syndrome
The report by Liu et al. (1) containing data from the International
ong QT Syndrome Registry regarding the risk factors for
ecurrent syncope and subsequent fatal or near fatal events in
hildren and adolescents with long-QT syndrome (LQTS) who
resent for evaluation after episodes of syncope is of great interest.
he registry includes all sorts of syncopal episodes, and in their
iscussion, Liu et al. aptly emphasize that risk stratification in
hese patients requires careful examination to distinguish whether
syncopal episode stemmed from LQTS-associated dysrhythmia
r whether it was simply a vasovagally mediated episode occurring
n an LQTS host.
In the general population, a vasovagal faint is by far the most
requent cause of syncope (2). It refers to a syncopal episode
nduced by a fall in blood pressure and cerebral hypoperfusion due
o reflex response upon various triggering factors (standing up,
rolonged orthostatic stress, reaction to blood taking, and so on).
he underlying mechanism is a loss of vasoconstrictor tone
ssociated with relative or absolute bradycardia. Although some
atients present with clear and prolonged premonitory symptoms,
cute onset has also been reported (3). In general, the overall
rognosis in patients with vasovagal syncope is excellent (4).
The lifetime cumulative incidence of 1 syncopal episode in
eenagers in the general population is high, with about 40% by age
1 years (2,5). This is almost identical to the cumulative prevalence
f 41% in children and adolescents with prolonged corrected QT
ntervals or young carriers of LQTS-causing mutations in the
tudy by Liu et al. (1). There is no reason to assume that vasovagal
yncope has a lower prevalence in patients with LQTS than in the
eneral population. Thus, whereas syncope in the setting of LQTS
s definitively a red flag, given the risk for fatal arrhythmic events
6), the epidemiological data on the frequency of vasovagal syncope
n the general population suggest that the vast majority of syncopal
pisodes in patients with LQTS are caused by vasovagal syncope.
he obvious challenge for clinicians is to identify the patients who
re at risk. With an additional positive family history of syncope or
udden death (3), the identification of high-risk patients would
possibly be more accurate.
Thus, although the risk for an aborted cardiac arrest or
LQTS-related sudden cardiac death rises with the occurrence of
syncopal episodes, syncope does not equate to torsades de pointes,
especially not in the young, and careful history taking remains a
cornerstone of diagnosis and treatment in these patients.
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Reply
We agree with Dr. Olde Nordkamp and colleagues that careful
history taking remains crucial for appropriate risk stratification and
management of patients with long-QT syndrome (LQTS) (as well
as other subjects with unexplained syncope). As Dr. Olde Nord-
kamp and colleagues note, this point was also emphasized in our
report in our discussion of the clinical implications of our findings
(1). However, we think that the comment regarding the fact that
the vast majority of syncopal episodes in patients with LQTS are
associated with a vasovagal mechanism may mislead readers to
underestimate the clinical importance of the development of
syncope in patients with LQTS. In this regard, it is important to
note that the sources Dr. Olde Nordkamp and colleagues cite
regarding a high frequency (41%) of syncopal episodes in general
population (obtained from questionnaire data in a relatively small
sample of medical students) may be an overestimation, as data
from other studies suggest that the frequency of syncope before age
18 years is much lower (approximately 15%) (2,3). Furthermore,
estimation of the frequency of vasovagal syncope in nonselected
patients is difficult, because in most studies, these events are not
thoroughly investigated, and this information may not take into
account the true penetrance of LQTS (or other arrhythmogenic
disorders) in the general population (4).
Information regarding the circumstances of syncopal events in
patients with LQTS in the registry was obtained prospectively and
carefully validated by study specialists. Our data consistently show
that among patients with LQTS, syncope is the most powerful
predictor of subsequent fatal or near fatal events. Importantly, the
present study shows that children and adolescents with LQTS who
experienced syncope had a pronounced 7- to 15-fold increase in
the risk for subsequent aborted cardiac arrest of sudden cardiac
death (1). These findings contrast those in the general population,
in which vasovagal events were shown to be associated with a
benign clinical course (3), and strongly suggest that the majority of
syncopal episodes in patients with LQTS should be considered
arrhythmic in nature until proven otherwise.
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Surgical Ablation for
Atrial Fibrillation
Not All Energy Sources
Are Created Equal
We read the recent report by Onorati et al. (1) with great interest.
We agree with the investigators that the effect of surgical lesion
pattern has been poorly investigated and had hoped that this report
would clarify the success of different lesion patterns in patients
undergoing concomitant surgery for atrial fibrillation. Unfortu-
nately, we believe that the report has several inherent flaws that
make the results inconclusive.
Most important, the left atrial group combined patients whose
lesions were created using different types of energy sources. Myriad
new ablation technologies have been introduced in the past decade,
and the ability of each to create transmural linear lesions varies.
Bipolar radiofrequency (RF) ablation appears more reliable in
creating transmural lesions than monopolar RF ablation (2). The
most likely reason that a change from monopolar RF to bipolar RF
ablation occurred after December 2003 was the improvement in
technology and thus outcomes. Fourteen of 32 patients undergoing
the limited approach had lesions created using monopolar RF
ablation. The “extensive” approach began in August 2004, after
bipolar RF ablation was introduced. This suggests that the
outcomes were inherently biased toward the “extensive group,” the
group with the better energy source. Even in the 18 patients who
underwent left atrial with bipolar RF ablation, the freedom from
atrial fibrillation in this series was 53%. We recently reported our
results in 175 patients using a left atrial–only approach, with
freedom from atrial fibrillation of 81% (3). It is difficult to account
for this disparity in results.
We congratulate Onorati et al. (1) for attempting to address a
ritical question: Does a more extended lesion set improve sinus
